Silence Therapeutics (SLN); to receive first research milestone for SLN500

Published on 24-09-2019 07:10:54
Author Sparks Team

Silence Therapeutics announced the triggering of the first $2m research milestone for SLN500 under the tie-up with global biopharmaceutical company Mallinckrodt Pharmaceuticals. Mallinckrodt has a choice to license up to two further complement-targeted assets in Silence’s preclinical complement-directed RNAi development programme.

Dr. David Horn Solomon, CEO, commented: “Our partnership with Mallinckrodt has proved both exciting and productive and the triggering of this first research milestone highlights the rapid progress which has been achieved to date through the collaboration. We remain committed to progressing SLN500 into clinical development and we look forward to further milestones as we rapidly develop this and potentially other innovative assets targeting the complement pathway.”

Share this with friends and colleagues